Healthcare >> CEO Interviews >> October 12, 2001
JOHN D. MENDLEIN is Chairman and CEO of Affinium Pharmaceuticals,
Inc. A senior executive with more than 15 years' experience in
the biotechnology industry, Dr. Mendlein joined Affinium in
November 2000 as Chairman and Chief Executive Officer. Prior to
joining Affinium, Dr. Mendlein served as Chief Knowledge Officer,
General Counsel and Senior Vice President, Intellectual Property
of Aurora Biosciences Corporation. He was appointed to the Aurora
Biosciences Board in November 2000 and to ACLARA BioSciences
(NSADAQ: ACLA) Board in 2003. Prior to joining Aurora in 1996,
Dr. Mendlein worked with the firm of Cooley Godward in Silicon
Valley, focusing on biotechnology transactions and intellectual
property. He is the author or inventor of over 30 articles,
reviews and patents. He was a Doctoral Trainee at Smith, Kline
and French Pharmaceuticals, in the Department of Molecular
Genetics, received his PhD from the University of California, Los
Angeles, for his work on the biochemistry and biophysics of
membrane proteins, and his JD from the University of California,
Hastings College of Law. Profile
Proteomics and an overview of things as they are now?
Dr. Mendlein: IPI was started on August 2, 2000. IPI was formed from
